Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Quantbot Technologies LP bought a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,575 shares of the company’s stock, valued at approximately $164,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in VRDN. FMR LLC boosted its stake in shares of Viridian Therapeutics by 16.8% during the 3rd quarter. FMR LLC now owns 11,183,478 shares of the company’s stock valued at $254,424,000 after purchasing an additional 1,610,130 shares in the last quarter. Parkman Healthcare Partners LLC bought a new stake in Viridian Therapeutics during the 3rd quarter valued at approximately $9,669,000. Victory Capital Management Inc. purchased a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $7,868,000. Lord Abbett & CO. LLC purchased a new position in shares of Viridian Therapeutics in the 3rd quarter valued at approximately $8,917,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at approximately $6,015,000.

Analyst Ratings Changes

VRDN has been the subject of several recent research reports. Wells Fargo & Company reissued an “equal weight” rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Needham & Company LLC restated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Finally, Royal Bank of Canada boosted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $14.44 on Monday. Viridian Therapeutics, Inc. has a one year low of $11.40 and a one year high of $27.20. The stock has a 50-day moving average of $16.75 and a 200 day moving average of $19.71. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -3.35 and a beta of 1.05.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.